Regulus Therapeutics Inc.
RGLS · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.42 | -0.08 | 0.07 |
| FCF Yield | -8.93% | -11.45% | -9.22% | -9.57% |
| EV / EBITDA | -6.43 | -5.14 | -5.51 | -9.80 |
| Quality | ||||
| ROIC | -14.96% | -17.93% | -17.43% | -11.93% |
| Gross Margin | 0.00% | -25.59% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.10 | 0.93 | 0.67 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 697,853.20% | 697,853.20% | 670,817.29% | 670,817.29% |
| Free Cash Flow Growth | 12.66% | -24.99% | 19.14% | -30.64% |
| Safety | ||||
| Net Debt / EBITDA | 4.56 | 3.01 | 1.85 | 1.45 |
| Interest Coverage | -619.88 | -1,057.38 | -3,042.00 | -211.38 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.03 |
| Cash Conversion Cycle | -211.76 | -501.35 | -792.00 | 2,611.01 |